Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $310000.0.

  • Orchestra BioMed Holdings' Capital Expenditures rose 35588.24% to $310000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $562000.0, marking a year-over-year increase of 21222.22%. This contributed to the annual value of $289000.0 for FY2024, which is 27051.28% up from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Capital Expenditures stood at $310000.0 for Q3 2025, which was up 35588.24% from $34000.0 recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Capital Expenditures high stood at $310000.0 for Q3 2025, and its period low was -$3000.0 during Q4 2023.
  • Its 4-year average for Capital Expenditures is $94266.7, with a median of $54000.0 in 2022.
  • As far as peak fluctuations go, Orchestra BioMed Holdings' Capital Expenditures crashed by 10555.56% in 2023, and later skyrocketed by 363333.33% in 2024.
  • Over the past 4 years, Orchestra BioMed Holdings' Capital Expenditures (Quarter) stood at $54000.0 in 2022, then crashed by 105.56% to -$3000.0 in 2023, then skyrocketed by 3633.33% to $106000.0 in 2024, then surged by 192.45% to $310000.0 in 2025.
  • Its last three reported values are $310000.0 in Q3 2025, $34000.0 for Q2 2025, and $112000.0 during Q1 2025.